| By Pharmatech

Brunei Darussalam is positioning itself as a future player in the regional pharmaceutical landscape by leveraging two strategic assets: its rich biodiversity and the rapidly expanding global halal market. Although the country’s pharmaceutical industry remains at an early stage, market indicators and policy support suggest strong long-term growth potential.

Early-Stage Industry With Strong Market Outlook

Brunei’s pharmaceutical sector is still in its infancy, yet its growth trajectory is promising. Business Monitor International (BMI) valued the market at around US$100 million in 2013, with a compound annual growth rate of approximately 9 percent projected through 2018, bringing the market value to an estimated US$150 million. This steady expansion reflects rising domestic demand and growing export-oriented ambitions, particularly in halal-certified medicines.

Biodiversity as a Foundation for Pharmaceutical Innovation

Located within one of the world’s most biodiverse regions, Brunei offers abundant natural resources that can support pharmaceutical research and development. Its forests contain a wide range of medicinal plants and bioactive compounds with potential pharmaceutical applications. Industry players note that while international researchers have shown interest, greater collaboration with universities, research institutes, and foreign experts is needed to fully unlock these natural assets and translate them into commercial products.

Halal Pharmaceuticals as a Strategic Growth Engine

The global halal market represents a major opportunity for Brunei’s pharmaceutical ambitions. In 2010, the Ministry of Religious Affairs introduced official guidelines for the manufacturing and handling of halal medicinal products, laying the regulatory foundation for halal pharmaceutical production. This move positioned Brunei to serve not only domestic demand but also international Muslim markets seeking Shariah-compliant healthcare products.

A key milestone came in 2013 with the establishment of Simpor Pharma, following full halal certification. Backed by a joint venture involving Canada-based Viva Pharmaceutical and Brunei-based investment partners, the company launched the country’s first pharmaceutical manufacturing facility. Early production focused on halal-certified capsules for export, highlighting Brunei’s intent to become a halal pharmaceutical export hub.

Government Incentives and Investment Appeal

Brunei’s macroeconomic stability strengthens its appeal to foreign investors. Recognized for political stability and a favorable tax environment, the country offers incentives such as reduced corporate income tax, exemptions from various business taxes, and grants for research, development, and training. The government has also actively promoted Brunei as a strategic base for regional expansion, attracting interest from Japan, Germany, and China for pharmaceutical research partnerships and raw material sourcing.

Structural Challenges and Infrastructure Gaps

Despite its advantages, Brunei faces structural challenges that could slow sectoral growth. Business processes such as company registration, contract enforcement, and property registration remain relatively cumbersome. Infrastructure limitations, particularly in research and large-scale manufacturing, also pose obstacles. Industry leaders point out that bureaucratic delays have previously prolonged project timelines, underscoring the need for regulatory streamlining and improved industrial facilities.

Future Prospects for a Halal-Focused Pharma Hub

Looking ahead, experts agree that sustained investment in human capital, research infrastructure, and regulatory reform will be critical for Brunei’s pharmaceutical ambitions. Developing local expertise in biotechnology and pharmaceutical sciences, while deepening cooperation with more established regional players, could help the country move up the value chain. With continued government commitment and rising global demand for halal medicines, Brunei’s pharmaceutical sector holds clear potential to evolve from an emerging market into a niche but competitive regional hub.

Original Article:

PharmTech. (2025). Brunei’s potential pharmaceutical market growth. Pharmaceutical Technology. https://www.pharmtech.com/view/bruneis-potential-pharmaceutical-market-growth